TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

Benzinga Logo Benzinga • •By Vandana Singh
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

GSK reported strong Q3 results with sales of $11.53 billion, an 8% increase at constant currency. The company raised its 2025 financial guidance, expecting sales growth of 6-7% and core earnings per share increase of 10-12%.

Insights
ROST   neutral

Listed as a top holding with $244.6 million allocation, no specific performance details provided


GSK   positive

Strong quarterly performance, raised financial guidance for 2025, growth in specialty medicines and vaccine sales, and CEO's optimistic outlook for 2026